TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis

Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility AnalysisSYDNEY, AUSTRALIA, March 13, 2026 ...
MPR

Phase 3 NSCLC Study of Eftilagimod Alfa Discontinued Following Interim Review

A phase 3 study of eftilagimod alfa for NSCLC is ending early due to futility, according to an update from developer Immutep.
Medscape

Staying the Course After EGFR Progression: A Practical Guide to Treatment in NSCLC

Dr Mark Kris highlights a recent study on osimertinib in NSCLC and outlines the best approaches for treatment beyond progression.
Clinical Trials Arena on MSN

Immutep’s LAG-3 hopes take a hit on Phase III NSCLC termination

The company will now assess the available data to determine its next steps in progressing efti’s development across multiple ...

Immutep stock tanks after futility analysis ends key lung cancer trial early

Immutep Limited IMMP shares are tumbling on Friday following the company’s update for the TACTI-004 Phase 3 trial. The Australia-based biotech announced that the Independent Data Monitoring Committee ...
ascopubs.org

Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC) harboring uncommon EGFR ...

GBC-11004: An AI-driven novel kinase target with potential to overcome osimertinib resistance in NSCLC. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...
Zacks.com on MSN

Novocure's Optune Lua Gets Japan Reimbursement for NSCLC Treatment

Novocure NVCR recently announced that Japan’s Ministry of Health, Labour and Welfare has approved reimbursement for Optune Lua through the country’s National Health Insurance program. In Japan, Optune ...